Part3: Introduction to Risk Based Qualification &rdan

/ Jo
Validation Section 1/2 an
m m
A
ub-
yo
i A
aj d
g .M
E n
-
018
l. 2
ri
A p
e,
r s
o u
g C
in
r ain
T
& V
Q
s ed
B a
k-Course: Risk-Based Approach for Commissioning, Qualification & Validation in Pharmaceutical
s
Training
Ri Industries/projects
Agon Academy, Risk-Based Q&V April. 2018-Eng.Majdi Ayoub
 an
Table of Content Jo rd
n /
mma
- A
ub
A. Functional areas Risk Assessment Survey yo
i A
aj d
B. Benefits of Based Risk Qualification .M
n g
C. Principles for Risk‐Based 1Qualification E
8-
2 0
D. Introduction about Risk r il. Assessment during
A p
cGMP project Lifecycle….to e, be continue…
r s
o u
C
E.Risk Based Qualification in g & Validation
r ain
F. Questions V
T and Answers
Q &
s ed
Ba
Video2 isk
-
R Agon Academy, Risk-Based Q&V
Risk Assessment Animation April. 2018-Eng.Majdi Ayoub 2
 an
A. Functional areas Risk Assessment Survey rd
/ Jo
n
mma
- A
ub
yo
i A
aj d
g .M Patient
n
8-E Impact
0 1
l. 2
pri
, A
r s e
o u
g C
in
r ain
T
& V
2006 Parenteral Drug Association survey on the functional area that has the most need for Risk Assessment
d Q
s e
a
k-B
R is Agon Academy, Risk-Based Q&V
April. 2018-Eng.Majdi Ayoub 3
 an
B. Benefits of Based Risk Qualification (1/4) rd
/ Jo
n
mma
- A
ub
yo
i A
aj d
g .M
E n
-
018
l. 2
ri
A p
e,
r s
o u
g C
in
r ain
T
& V
d Q
a se
k-B
Ris Agon Academy, Risk-Based Q&V
April. 2018-Eng.Majdi Ayoub 4
 an
B. Benefits of Based Risk Qualification (3/4) rd
/ Jo
n
mma
- A
ub
yo
i A
aj d
g .M
E n
-
018 Risk
l. 2
ri Management
A p
e, can reduce
r s
o u extra works
g C
in
r ain
T
& V
d Q
a se
k-B
Ris Agon Academy, Risk-Based Q&V 7
April. 2018-Eng.Majdi Ayoub
5
 an
B. Benefits of Based Risk Qualification (4/4) rd
/ Jo
n
mma
- A
ub
yo
i A
aj d
g .M
E n
-
018
l. 2
ri
A p
e,
r s
o u
g C
in
r ain
T
& V
d Q
a se
k-B
Ris Agon Academy, Risk-Based Q&V
April. 2018-Eng.Majdi Ayoub
6
C. Principles for Risk‐Based Qualification an
rd
o
` ma
n / J

A m
1 b-
Focus on that which affects product quality
o u
A y
2 di subordinate to PQ)
Process User Requirements key to acceptability (IQ/OQ
aj
3 Risk assessments and process knowledge used to
M
g. identify critical elements
E n
8 -
4 1
Only critical features/functions to be qualified
0
l. 2
5 All activities must contribute valuep ri
e,A
6 Value‐added documents based
u rs on technical merit
C o
7 g
Use of supplier documentation
in
r a in
8 Test planningT(and one‐time testing)
& V
d Q
a se
k-B
is
R Agon Academy, Risk-Based Q&V 9
April. 2018-Eng.Majdi Ayoub 7
D. Introduction about Risk Assessment during cGMP project Lifecycle (1/15) n
d a
o r
Normal Turnkey Project Sequence n / J
mma
- A
ub
yo
i A
aj d
g .M
Construction
E n Commissioning Handover &
Conceptual
Design
Basic Design
Detailed
Engineering 1 8&- & Operational
2 0
Procurement Qualification Support

ri l.
A p
e,
Identify Select I…….……….Define……I I………..…..Execute………...……I
rs
Operate……>>
o u
Identify : Commercial and technical concept
g C is pinned down; its feasibility is considered proven by the end of Identify.
n outlined; one is selected for further development by the end of Select.
Select : Several conceptual options iare
n
r ai including all baselines; it is sanctioned by the end of Define [final investment
Define : Selected option is developed,
T
V
decision (FID)].
& is being implemented and completed by the end of Execute.
Execute: Approved project
d Q
Operate: After commissioning and startup, project is in operations during its lifetime and decommissioned by the end
e
ofsOperate
a
k -B
is
R Agon Academy, Risk-Based Q&V
April. 2018-Eng.Majdi Ayoub 8
D. Introduction about Risk Assessment during cGMP project Lifecycle (2/15) n
d a
o r
In Which Area Can I use Risk Assessment
n / J
mma
2.RA During Construction-A
1.RA During Design ub Component
o
and Commissioning
y Impact
i A Assessment
aj d
g .M
Construction
E n Commissioning Handover &
Conceptual
Design
Basic Design
Detailed
Engineering 1 8&- & Operational
2 0
Procurement Qualification Support

ri l.
A p
e,
Product r s
Patient o u Leveraging Risk 3.RA During
g C Assessment
n Operation for
in i (Example
a whole process
1.Design 2.SystemT
r provided)

& V
Q
s ed
Ba 3.Process

k-
is
R Agon Academy, Risk-Based Q&V
April. 2018-Eng.Majdi Ayoub 9
D. Introduction about Risk Assessment during cGMP project Lifecycle (3/15) an
rd
Project Definition, Execution, Value, and Outcome / Jo
n
mma
- A
ub
yo
i A
aj d
g .M
E n
-
018
l. 2
ri
A p
e,
r s
o u
g C
in
r ain
T
& V
d Q
a se Over all Project RA

k-B
Ris Agon Academy, Risk-Based Q&V
April. 2018-Eng.Majdi Ayoub 10
D. Introduction about Risk Assessment during cGMP project Lifecycle (4/15)
Link between Normal Project Sequence and Outcomes an
r d
/ Jo
n
FDI mma
- A
ub
Conceptual Detailed
Construction
yo
Commissioning Handover &
Design
Basic Design
Engineering
& &
i A Operational
Procurement
aj d
Qualification Support

g .M
E n
Identify 8-
Select I…….……….Define……I I………..…..Execute………...……I Operate……>>
2 01
l.
pri
, A
r s e
o u
g C
in
r a` in
` ` T ` `
& V
d Q
a se
k-B
Ris 13
Agon Academy Eng.Majdi Ayoub 2018 11
 D. Introduction about Risk Assessment during
RA for Design cGMP project Lifecycle (5/15)
an
Conceptual Design Risk Overview r d
Jo
/Product
n
Conceptua Detailed
Construction Commissioning Handover &
m ma Patient
&
l Design
Basic Design
Engineering
& A
Operational
-
Procurement Qualification b
Support
u
1.Design 2.System

yo
i A 3.Process

aj d
Data Integrity Risk Layout Risk
g .M Return of Investment Risk

E n
-
018
l. 2
r i
A p
e,
r s
o u Risk Constrains for
g C Conceptual
in
r ain Design
T
& V
Q
s ed
Ba
k-
s
i Regulatory Requirement Risk Delivery
R GMP Requirements Risk
Agon Academy Eng.Majdi Ayoub 2018 12
 D. Introduction about Risk Assessment during
RA for Design
cGMP project Lifecycle (6/15)
an
Conceptual Design Risk Overview rd
GMP Risk Analysis/GMP Requirements Risk / Jo
n
Process Potential (Consequences) Control Procedure ma Risk
Description Failure Mode -Am Mitigation
ub
Lack of proper URS does not Business and o
‐ URS to be prepared by Consultant
y
Machine URS consider the compliance A
and reviewed by business
i
owner
cGMP parts impact team
j d
a to be
‐ Quality involvement
g
considered M
.in early phase
E n vs. system/design
‐ New regulation
8- must be considered
update
1
Rooms Wrong Room Process Impact
0
‐. 2 Layout with room data sheet to be
Suitability Size
pril provided Include all
control
, A ‐ GMP design constrains to be
r s e considered (process, material, procedure in
Conceptual
o u personnel flows)
Conceptual
C
ing
Location Location of the Business, process ‐ Historical data for the location is design.
Suitability plants was not and compliance required
properly ain impact ‐ Neighbor process to be considered
T
configures
r ‐ Future expansion to be considered.
Process & V
Process was Planning and ‐ Market demand and growth to be
Suitability d Q
not properly registration determined
a se defined. impact ‐ Formulation team to be involved.

k-B ‐ URS to meet the process needs

R is ‐ Process diagram to be included

Agon Academy, Risk-Based Q&V
April. 2018-Eng.Majdi Ayoub 13
 D. Introduction about Risk Assessment during
RA for Design
cGMP project Lifecycle (7/15)
an
r d
Jo
/ Overview
Basic and Detailed Engineering Design Risk n
a Product
m m Patient
Construction Commissioning Handover -&A
Conceptua Basic Detailed
& &
u b
Operational
l Design Design Engineering
Procurement Qualification
y o
Support 1.Design 2.System

i A
aj d 3.Process

Design deliverable Risk g .MUtilities Risk

Financial Risk
E n
1 8-
2 0
r il.
A p
e,
r s
o u
C Risk Constrains
n ing for Detailed
r ai design
T
& V
d Q
a se
k-B
R is
Regulatory Requirement GMP Requirements Risk Recourses
Agon Academy Eng.Majdi Ayoub 2018 14
 RA for Design
D. Introduction about Risk Assessment during
cGMP project Lifecycle (8/15)
an
Basic and Detailed Engineering Design Risk Overview
o rd
GMP Risk Analysis/GMP Requirements Risk n /J
Process Potential m a Risk
Description Failure Mode
(Consequences) Control Procedure
A m Mitigation
b -
‐ URS for the project to be o u
Wrong Business and determined
A y
Machine URS machine compliance ‐ Utilization study to
j dibe included
Specification impact ‐ Quality involvementa to be
M
considered .in early phase
g
n
Need for
8
‐ Quality-ETeam and responsibility will
be1assigned at early phase of the
Retrospective
Late Quality
validation &
Compliance 0
2 project
Enrollment Impact l.
i ‐ cGMP Quality Plan to be assigned Include all
Reworks will be
p r control
needed
, A procedure
s e
rprocess ‐ Consultant pre‐evaluation to be before
Consultant is
o u
Business, conducted Construction
andCcompliance
Consultant not qualified
‐ Third party check is preferable
Qualification for such
in g
impact ‐ Steering team approval before
phase is started
pharma project
a i n release.
T r
‐ Preparation the Risk Assessment in
Lack ofVRisk
Q &
assessment
Business,Planning, early phase
Lack of Risk process and ‐ Risk Assessment to be prepared for
Assessments edcould cause compliance other phase according to suitability
a adverse
k-B consequences
impact for each phase

R is ‐ Periodic Risk assessment review

Agon Academy, Risk-Based Q&V
April. 2018-Eng.Majdi Ayoub 15
 D. Introduction about Risk Assessment during
cGMP project Lifecycle (9/15)
an
Leveraging Risk Construction/Commissioning and Validation Risk Overview o rd
Assessment n /J
m aProduct
Patient
Construction Commissioning Handover & A m
Operational b-
Conceptu Basic Detailed &
&
Support u
al Design Design Engineering 1.Design 2.System
Procurement Qualification
y o
i A
aj d 3.Process

g . M
ASTM E2500 n
E
1 8-
2 0
r il.
A p
e,
r s
o u
g C
in
r ain
T
& V
Including:
Q
‐ Commissioning
s ed
a
‐ Qualification‐
B
k -
s
‐ Validation
RiAgon Academy Agon Academy , Eng.Majdi Ayoub 2018
Eng.Majdi Ayoub 2015 16
 D. Introduction about Risk Assessment during
cGMP project Lifecycle (9/15)
an
Leveraging Risk Construction/Commissioning and Validation Risk Overview o rd
Assessment n /J
m aProduct
Patient
Construction Commissioning Handover & A m
Operational b-
Conceptu Basic Detailed &
&
Support u
al Design Design Engineering 1.Design 2.System
Procurement Qualification
y o
i A
aj d 3.Process

ASTM E2500
g .M
E n
1 8-
2 0
r il.
A p
e,
r s
o u
g C
in
r ain
T
& V
Q
s ed
Ba ISPE2011
k -
s
Ri Agon Academy , Eng.Majdi Ayoub 2018 17
 Leveraging Risk D. Introduction about Risk Assessment during
Assessment cGMP project Lifecycle (10/15)
an
Construction/Commissioning and Validation Risk Overview o rd
n /J
m aProduct
Patient
Construction Commissionin Handover & A m
Conceptu Basic Detailed
& g& Operational b -
al Design Design Engineering
Procurement Qualification Support
o u 1.Design 2.System

A y
j di 3.Process

a
g M
. Quality System
Project Management Risk Commissioning/
Qualification Risk -E
n
1 8
2 0
r il.
A p
e,
r s
o u
g C Bad Construction/
n in Commissioning,
r ai Validation
T
& V
Q
s ed
B a
k-
s
Ri Procurements Risk Licensing and Authorization Recourses
Agon Academy , Eng.Majdi Ayoub 2018 18
D. Introduction about Risk Assessment during cGMP project Lifecycle (11/15) an
r d
Construction/Commissioning and Validation Risk Overview n/ Jo
m a
Product
A m Patient
cGMP Systems undergoing Qualification and Validation Scope ub-
yo
i A 1.Design 2.System

aj d
g .M
E n 3.Process

1 8-
2 0
r il.
A p
e,
r s
o u
g C
in
r ain
T
& V
Q
s ed
Ba
k-
s
Ri Agon Academy, Risk-Based Q&V
April. 2018-Eng.Majdi Ayoub 19
 D. Introduction about Risk Assessment during cGMP project Lifecycle (12/15)
Construction/Commissioning and Validation Risk Overview an
r d
/ Jo
cGMP Systems undergoing Qualification and Validation Scope n
ma
System

Sub‐
A m
b -
system
u
o Qualif./
A y
j di Valid. point
Product
a Patient
g .M
En
8-
1.Design 2.System

0 1
. 2
ril
3.Process

A p
e,
r s
o u
g C
in
r ain
T
& V
d Q
a se
k-B
R is
22 20
 D. Introduction about Risk Assessment during cGMP project Lifecycle (13/15)
Construction/Commissioning and Validation Risk Overview an
r d
Scope of Q&V within 3 Process Validation Step / Jo
n
Conceptual Detailed
Construction
Commissioning & m ma
Handover &
Design
Basic Design
Engineering
&
Qualification - AOperational
Procurement
ub Support

yo
i A Product
aj d Patient

g .M
E n
- 1.Design 2.System

0 18
l. 2
i 3.Process

pr
e,A
u rs
C o
in g
r ain
T
& V
d Q
a se
k-B
R is
Agon Academy, Risk-Based Q&V
April. 2018-Eng.Majdi Ayoub 21
 Leveraging Risk D. Introduction about Risk Assessment during
Assessment cGMP project Lifecycle (14/15)
an
Construction/Commissioning and Validation Risk Overview o rd
n / J
Leveraging Approach a
Construction
m m
Handover &
Commissioning &
Conceptual
Design
Basic Design
Detailed
Engineering
&
Qualification b-
A Operational
Procurement
o u Support

A y
j di
a
g . M Product
Patient
n
8 -E
0 1 1.Design 2.System

l. 2
p ri 3.Process

e,A
u rs
C o
in g
r ain
T
V
Q&
s ed
Ba
k-
s
Agon iAcademy, Risk-Based Q&V
R
April. 2018-Eng.Majdi Ayoub
22
 Leveraging Risk D. Introduction about Risk Assessment during
Assessment cGMP project Lifecycle (15/15)
an
Construction/Commissioning and Validation Risk Overview o rd
n / J
Leveraging Approach a
Construction
m m
Handover &
Commissioning &
Conceptual
Design
Basic Design
Detailed
Engineering
&
Qualification b-
A Operational
Procurement
o u Support

D e s i g n Q u a i I f i c a t i o n /R e v i e w Monitoring and A y
Control
j di cGMP
Purchasing Controls a
g .M Practices
E n
1 8-
` 2 0
r il.
A p
e,
r s
o u
g C Product
in Patient

r ain
T 1.Design 2.System

& V
Q 3.Process

s ed
B a
k-
s
Ri Plan Plan + Execute
Commissioning+
Documentation
Q&V +
Documentation
Agon Academy , Eng.Majdi Ayoub 2018 23
 an
rd
/ Jo
n
mma
- A
ub
yo
i A
aj d
.M
Section D2018:-E to be n g

r il.
continued
ur
s e, A p
in part 2/2
C o
in g
Video 11 about Validation
n
ai 17:09
Video Link : After
r
T Field
to 20:28‐Green
V
ProjectQ&
s ed
a 12 about Validation,
Video
B
k-
s
i continue Green Field project
R Video Link : After 00 to 01:15 Agon Academy, Risk-Based Q&V April.
2018-Eng.Majdi Ayoub 24